Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,19 +4,14 @@
4	4
5	5	= Summary =
6	6
7		-Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country.
	7	+* Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country.
	8	+* Torrent Pharma widespread global presence in over 40 countries.
	9	+* The Company has cumulatively filed 818 patent applications for NCEs from these and earlier projects in all major markets of which, 497 patents were granted so far.
	10	+* The company's state-of-the art R & D Centre at Bhat near Ahmedabad is spread out over 125,000 Sq. mts. with a built-up area of 41,000 Sq. mts
8	8
9		-Torrent Pharma widespread global presence in over 40 countries.
10	10
11		-The Company has cumulatively filed 818 patent applications for NCEs from these and earlier projects in all major markets of which, 497 patents were granted so far.
12		-
13		-The company's state-of-the art R & D Centre at Bhat near Ahmedabad is spread out over 125,000 Sq. mts. with a built-up area of 41,000 Sq. mts
14		-
15		-
16		-
17	17	[[image:TORNTPHARM0.jpg||height="490" width="718"]]
18	18
19		-
20	20	= Company Overview =
21	21
22	22
...	...	@@ -80,7 +80,6 @@
80	80	|(% style="width:91px" %)2017|(% style="width:849px" %)Acquired Women Healthcare brands from Novartis
81	81	|(% style="width:91px" %)2021|(% style="width:849px" %)Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 in India
82	82
83		-
84	84	== Manufacturing Facilities ==
85	85
86	86	Torrent Pharma has robust manufacturing technologies and manufacturing facilities.{{footnote}}https://torrentpharma.com/index.php/site/info/manufacturing{{/footnote}}
...	...	@@ -97,7 +97,6 @@
97	97	|(% style="width:264px" %)Pithampur|(% style="width:162px" %)52,342 sq. mtrs.|(% style="width:251px" %)153 Mn
98	98	|(% style="width:264px" %)Levittown Pennsylvania|(% style="width:162px" %)19,020 sq mtrs.|(% style="width:251px" %)120 Mn
99	99
100		-
101	101	[[image:TORNTPHARM2.png]]
102	102
103	103
...	...	@@ -342,7 +342,6 @@
342	342	|(% style="width:233px" %)**CRAMS/others**|(% style="width:119px" %)517|(% style="width:81px" %)6%|(% style="width:117px" %)472|(% style="width:91px" %)6%|(% style="width:92px" %)10%
343	343	|(% style="width:233px" %)**Total**|(% style="width:119px" %)8,005|(% style="width:81px" %)100%|(% style="width:117px" %)7,939|(% style="width:91px" %)100%|(% style="width:92px" %)1%
344	344
345		-
346	346	Torrent’s four major pharma markets are India, US, Germany and Brazil. The Company’s strategic priorities in India and Brazil continue to focus on strengthening specialties, field force productivity and new product development. These markets remain a key priority for the Company and offer higher visibility and sustainability to the business. In the US and Germany, the Company continues to focus on its new product pipeline by developing complex products.
347	347
348	348
...	...	@@ -416,7 +416,6 @@
416	416	* Profit before tax at Rs. 484 crores was up by 20%.
417	417	* Net profit after tax at Rs. 330 crores was up 2.8%.
418	418
419		-
420	420	**India**
421	421
422	422	* India revenues at Rs 1,093 crores grew by 18%.
...	...	@@ -425,7 +425,6 @@
425	425	* PCPM for the quarter was Rs 10 lakhs with an MR strength of 3,600
426	426	* Torrent has launched its Trade Generics division during the quarter.
427	427
428		-
429	429	**United States**
430	430
431	431	* US revenues at Rs 266 crores, were down by 29%.
...	...	@@ -433,7 +433,6 @@
433	433	* Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities.
434	434	* As on June 30, 2021, 54 ANDAs were pending for approval with USFDA and 7 tentative approvals were received, including 1 tentative approval received during the quarter.
435	435
436		-
437	437	**Brazil**
438	438
439	439	* Brazil revenues at Rs 153 crores, were up by 9%
...	...	@@ -440,7 +440,6 @@
440	440	* Constant currency sales at R$ 108 million, was up by 14% versus covered market growth of 12%
441	441	* Growth was driven by growth momentum in boththe branded and generic segment. New products have contributed to 3% growth.
442	442
443		-
444	444	**Germany**
445	445
446	446	* Germany revenues at Rs 260 crores were up by 5%
...	...	@@ -447,7 +447,6 @@
447	447	* Constant currency sales were Euro 29 million with flat growth.
448	448	* Second wave of Covid and related lockdowns impacted the market growth during the quarter.
449	449
450		-
451	451	= References =
452	452
453	453	{{putFootnotes/}}